WINTON GROUP Ltd Invests $174,000 in InMode Ltd. (NASDAQ:INMD)

WINTON GROUP Ltd purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,446 shares of the healthcare company’s stock, valued at approximately $174,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Systematic Financial Management LP raised its holdings in shares of InMode by 13.3% in the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after purchasing an additional 115,492 shares in the last quarter. Barclays PLC increased its holdings in InMode by 113.5% during the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after buying an additional 90,173 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in InMode by 54.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock worth $2,127,000 after buying an additional 44,058 shares in the last quarter. State Street Corp lifted its holdings in InMode by 3.7% during the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock worth $34,657,000 after buying an additional 73,183 shares during the period. Finally, Atlas Legacy Advisors LLC bought a new stake in InMode during the 4th quarter valued at $848,000. Institutional investors own 68.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Barclays upped their price objective on InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, InMode has an average rating of “Hold” and a consensus price target of $22.25.

InMode Price Performance

InMode stock opened at $17.74 on Tuesday. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $21.76. The business has a fifty day moving average price of $18.34 and a 200-day moving average price of $17.79. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 7.55 and a beta of 2.08.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.